India plans periodic inspections of all clinical-trial sites

05/5/2013 | Business Standard (India)

India's Drug Controller General office announced plans to inspect all of the nation's clinical-trial sites at least annually to verify regulatory compliance. The inspections will cover Schedule Y drugs, good clinical practice, and other regulatory requirements. The move follows criticism of the agency's failure to monitor human clinical trials more closely and accompanies several other recent measures, including establishing an ethics committee and setting guidelines for compensation to those injured in clinical trials.

View Full Article in:

Business Standard (India)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD